黄芪注射液对慢性心力衰竭患者血浆凋亡相关因子的影响

作者	单位
张金国	山东济宁医学院附属医院心内科
杨娜	河北省人民医院心脏中心
何华	山东济宁医学院附属医院心内科
魏广和	山东济宁医学院附属医院心内科
高东升	山东济宁医学院附属医院心内科
王学忠	河北省人民医院心脏中心
宋光耀	河北省人民医院心脏中心

摘要点击次数: 1373

全文下载次数: 1339

中文摘要:

目的探讨黄芪注射液对慢性心力衰竭(chronicheartfailure,CHF)患者血浆凋亡相关因子可溶性Fas(solubleFas,sFas)、可溶性Fas配体(solubleFasL ,sFasL)及肿瘤坏死因子α(tumornecrosisfactoralpha,TNF -α)的影响。方法将84例NYHA心功能分级属Ⅱ～Ⅳ级的CHF患者随机分为黄芪治疗组(治疗组,42例)和常规治疗组(对照组,42例) ,两组于治疗前后分别测定血浆sFas、sFasL、TNF- α水平,同时评估NYHA心功能分级,测定左室功能指标。结果治疗后两组NYHA心功能分级均较治疗前改善(P <0 . 0 5或P <0 . 0 1) ,且治疗组优于对照组(P <0. 0 5) ;治疗组左室收缩末期容积(leftventricularend systolicvolume ,LVESV)、左室舒张末期容积(leftventricularend diastolicvolume,LVEDV)减小,左室射血分数(leftventricularejectionfraction ,LVEF)提高,与治疗前比较差异有显著性(P <0 . 0 5) ;治疗组血浆sFas、sFasL、TNF -α水平明显下降,与本组治疗前及对照组治疗后比较差异有显著性(P <0. 0 5或P <0. 0 1) ,对照组除TNF -α与治疗前比较差异有显著性(P <0 .0 5)外,余均无明显变化。结论黄芪注射液能够降低CHF患者血浆凋亡相关因子水平,可作为治疗CHF有效药物之一。

英文摘要:

ObjectiveTo investigate the effect of Astragalus injection(AGI) on serum apoptosis related factors such as soluble Fas (sFas), soluble Fas ligand (sFasL) and tumor necrosis factor alpha (TNF-α) in patients with chronic heart failure (CHF). MethodsEighty-four patients with CHF of NYHAⅡ-Ⅳ grade were randomly divided into two groups, the treated group (42 patients) treated with AGI and the control group (42 patients) treated with routine treatment. The level of serum sFas, sFasL and TNF-α were measured with ELISA before and after treatment. At the same time, patients’ heart function were graded according to the NYHA classification and their indices of left ventricular function were determined. ResultsPatients’ NYHA grade was improved in both groups after treatment (P<0.05 or P<0.01), and it was better in the treated group than that in the control group (P<0.05). Moreover, in the treated group, the left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) decreased, the left ventricular ejection fraction (LVEF) increased, which was significantly different than that before treatment (P<0.05) respectively; level of serum apoptosis related factors sFas, sFas L and TNF-α were significantly decreased after treatment, showing significant difference as compared with those before treatment or with those in the control group after treatment (P<0.05 or P<0.01). While all indices had no obvious change in the control group. ConclusionAGI may be regarded as an effective remedy for treatment of CHF owing to its effects in decreasing the level of serum apoptosis related factors in patients with CHF.

关闭